Cipla Limited — Investor Meet, 02-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Cipla Ltd reported strong Q2 FY25 results, achieving an EBITDA margin of 26.7%, the highest ever for the company. Revenues grew 9% year-on-year, with notable growth in chronic therapy segments. Despite challenges in trade generics and regulatory inspections, particularly at its Goa facility, Cipla remains optimistic about an upcoming recovery. The company continues to invest in its workforce and has expanded its product portfolio. Strong performance was also noted in its Consumer Health and One Africa segments.